Clinical Trial Research
Oncothyreon Presents Data from Phase 1/2 Trials of PX-866 in Combination with Docetaxel and with Cetuximab at 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Published in Gene Therapy Weekly, December 1st, 2011
2011 DEC 1 -- Oncothyreon Inc. (Nasdaq: ONTY) announced the presentation of data from two Phase 1/2 trials of PX-866, an irreversible, pan-isoform phosphatidylinositol-3-kinase (PI-3K) inhibitor, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco, California. Results presented highlighted findings from the Phase 1 dose-escalation portions of Phase 1/2 trials evaluating PX-866 in combination with docetaxel (Taxotere(®)) and PX-866 in combination with cetuximab (Erbitux®).
PX-866 in Combination with Docetaxel
The Phase 1 portion of the Phase 1/2 trial of PX-866 in...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2011-12-01)
More Articles from Gene Therapy Weekly
- Gene Therapy
Engineered, drug-secreting blood vessels reverse anemia in mice - Prostate Cancer
New Findings Reported from Third Affiliated Hospital Describe Advances in Prostate Cancer - Gene Therapy
New Findings from Institute for Advanced Medical Sciences Describe Advances in Gene Therapy - Gene Therapy
New Gene Therapy Research from Ohio State University Discussed - Gene Therapy
New Gene Therapy Study Findings Reported from M. Decressac and Co-Authors - Gene Therapy
New Gene Therapy Study Findings Reported from School of Medicine - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
